JUST RIGHT.

WHETHER YOU RUN 24, 240 OR EVEN 2,400 SAMPLES A DAY,
FRAGMENT ANALYZER™ IS JUST RIGHT.

Qualify and quantify nucleic acids for ANY throughput.
Streamline sample analysis for ANY application.

NGS QC  RNA QC  gDNA  SSRs

More at AATI-US.COM
Bulk M-MLV and RNasin at competitive prices

◎ M-MLV (H-) Reverse Transcriptase
US$1.5 per KU for more than 1,000 KU

- H minus Moloney Murine Leukemia Virus (M-MLV) Reverse Transcriptase is a recombinant M-MLV reverse transcriptase. RNase H activity has been eliminated by a point mutation in the RNase H domain of M-MLV RTase, ensuring high yields.
- Deficient RNase H activity to reduce RNA template degradation during the first-strand cDNA synthesis.
- cDNA up to 12 kb.

◎ RNasin (RNase inhibitor)
US$6.7 per KU for more than 100 KU

RNasin is a ribonuclease inhibitor extracted from human placenta with a molecular weight 51 kDa. It inhibits the activity of RNase by specifically binding up to RNase with a non-covalent bond. RNasin, free of RNase or Nickase, can maintain its activity at pH from 5 to 8, and the highest one at pH 7.8.

Beijing SBS Genetech Co. Ltd.
Fax: +86-10-82784290
Email: order@sbsbio.com
Website: www.sbsbio.com
Success is contagious

In 2011, Ion AmpliSeq™ technology enabled targeted sequencing from as little as 1 ng of DNA. And the world responded.

In just four years we’ve designed over 25,000 custom panels for researchers around the world. And now, with as little as 1 ng, you can easily target sets of genes, and make sequencing a success for even old or degraded FFPE samples. Now that’s an idea worth spreading.

Ion AmpliSeq technology—because every sample matters.
Get more from your samples at thermofisher.com/ampliseq

For Research Use Only. Not for use in diagnostic procedures. © 2015 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. CO019151 1015
BD FACSseq™ Cell Sorter and BD™ Precise Assays
Gene expression assays for single cells

NGS-ready samples for gene expression
Thousands of single cells, individually barcoded and indexed, now at the transcript level

The new BD FACSseq™ cell sorter selects thousands of individual cells, quickly discarding any dead/dying cells and then isolating them into PCR plates that contain preloaded BD™ Precise reagents for your customized targeted gene expression assays. A much simplified workflow prepares the samples for absolute and direct molecular counting of transcripts by next generation sequencing (NGS), while minimizing amplification bias that can potentially occur in these crucial steps.

The affordable BD FACSseq cell sorter combined with BD Precise assays lets you easily amp up your lab's productivity to help ensure that your high-quality single cell samples are ready for gene expression assays. And, you can significantly increase data accuracy and throughput while controlling costs.

Find out how at bdbiosciences.com/go/facsseq

Class 1 Laser Product.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2015 BD
23-17810-00
The S is for Simplicity

The new Ion S5™ System. Targeted sequencing has never been simpler.

Simple library prep tools, cartridge-based reagents and automated data analysis have reduced DNA-to-data hands-on time to less than 45 minutes. So you’ll spend less time doing routine molecular biology, and more time informing time-sensitive decisions.

- **Ion AmpliSeq™ technology**
  As little as 1 ng low-quality DNA sample input for library prep

- **Cartridge-based reagents**
  Less than 15 minutes of sequencing setup time

- **2.5 to 4 hours of run time**
  Fastest run time of any benchtop sequencer

Watch the Ion S5 System in action at [thermofisher.com/ionS5](http://thermofisher.com/ionS5)

*For Research Use Only. Not for use in diagnostic procedures. © 2015 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. CO019129 1015*
A SMARTer®, Highly Sensitive Tool for Library Prep from Picogram Inputs of Total RNA

SMARTer Stranded Total RNA-Seq Kit - Pico Input Mammalian

Our complete solution for 250 pg–10 ng of total RNA

Robust RNA-seq library construction from very low amounts of starting material is challenging, especially with FFPE and laser capture microscopy samples. Our newest release, the SMARTer Stranded Total RNA-Seq Kit - Pico Input Mammalian, excels with input amounts as low as 250 pg of total mammalian RNA. Improve your NGS library prep from picogram amounts of total RNA with a novel, sensitive, and ligation-free kit that generates stranded, Illumina®-ready libraries in 5 hours.

To get started, visit www.clontech.com/total-RNAsseq-pico

Scan to find out more
Tumor Genomic Profiling Services
for Clinical Trials

Comprehensive Coverage, Tailored Results

Based on the Accuracy and Content Enhanced (ACE) platform, our advanced tumor profiling services provide the most complete genomic data from any tumor sample type. Our cancer panel includes coverage of over 1,300 genes, including clinically actionable genes, known driver mutations, immuno-oncology and key cancer pathway genes. Our service is tailored to address the needs of your clinical trial enrollment requirements while simultaneously making a broader research dataset available. As a result, we maximize the return on every tumor sample.

- DNA and RNA analysis from a single sample for maximum insight
- More coverage of key cancer pathway genes
- Alterations reported include SNVs, CNVs, gene fusions and low-level variant expression
- Comprehensive analysis with flexible reporting of the complete panel or a focused set of genes, depending on your requirements

www.personalis.com | info@personalis.com
+1 855-GENOME4 (436-6634)
+1 650-752-1300 (outside U.S.)

© 2015 Personalis, Inc. All rights reserved. Personalis® is a registered trademark of Personalis, Inc., in the United States and/or other countries.
Epigenetics
in Drug Discovery
26 - 27 January 2016  Cambridge, UK

Keynote Speaker
Rabinder Prinjha
Vice President
GlaxoSmithKline

Agenda Topics
• DNA Methylation
• Histone Modifications
• Next Generation Epitherapeutics
• Regulation of Genomic Functions

Register now at
SELECTBIO.com/EGDD2016
Save up to £100 with our Early Bird
discount (expires 15th December 2015)

enquiries@SELECTBIO.com   +44 (0)1787 315110
Woodview, Bull Lane, SUDBURY, CO10 0FD, UK
Looking for
A Genomic Research Partner?

Next-Generation Sequencing (NGS)
Whole genome Sequencing (HiSeq X Ten)
Exome Sequencing
Targeted Sequencing
Long Read Sequencing
Transcriptome Analysis, small RNA
Epigenomics

Bio Informatics
Assembly / Mapping
Variant (SNP / Indel) calling
CNV & Breakpoints
Expression Profiles
DEGs / miRNA
Enrichment Profiles
Gene Annotation

Capillary Sequencing
Microarray
Oligonucleotide Synthesis
Genetically Engineered Mouse
Expand Your Epigenetics Discovery by Sequencing More of the Methylation

Accel-NGS® Methyl-Seq Library Kit for Illumina® Platforms

- Simple 2 hour protocol
- DNA inputs from 100 pg to 100 ng
- Low bias library preparation
- Compatible with WGBS, RRBS, and other enrichment methods

www.swiftbiosci.com

© 2015, Swift Biosciences, Inc. The Swift logo is a trademark and the Accel-NGS logo and Accel-NGS are registered trademarks of Swift Biosciences. Illumina is a registered trademark of Illumina, Inc. 09/15, 15-0399
The Department of Epigenetics and Molecular Carcinogenesis at The University of Texas MD Anderson Cancer Center, Science Park, http://sciencepark.mdanderson.org, seeks applications for a term tenure-track position at the Assistant Professor level. Research in the department encompasses cellular, genetic and epigenetic mechanisms important to oncogenesis and tumor suppression, stem cell pluripotency, immune cell function, cell death mechanisms, and genome integrity. We seek individuals working in these areas, with preference for strong bioinformatics expertise. Candidates must be committed to working in a highly collaborative, interdisciplinary environment. The successful candidate will be expected to develop and maintain an internationally recognized and competitively funded research program, and to participate in graduate student training. The department has outstanding core support services, including facilities for analysis of genetically engineered mouse models, imaging, and next generation sequencing. The department is located in a pine-oak forest near the city of Austin, TX, but is closely aligned with the main MD Anderson campus in Houston. MD Anderson offers outstanding research facilities, startup packages, and faculty benefits. Required qualifications include a Ph.D. (or equivalent), postdoctoral or independent scholarly research experience, and a strong publication record.

Candidates should submit a cover letter outlining the relevance of their research experience and interests to the position description, statement of current and proposed research interests, names and contact information for three references, and a CV as a single PDF to sciencepark@mdanderson.org by January 1, 2016.

MD Anderson is an equal opportunity employer and does not discriminate on the basis of race, color, religion, age, national origin, sex, sexual orientation, gender identity/expression, disability, veteran status, genetic information or any other basis protected by federal, state or local laws, unless such distinction is required by law. All positions at The University of Texas MD Anderson Cancer Center are security sensitive and subject to examination of criminal history record information. Smoke-free and drug-free environment.

CANCER INSTITUTE DIRECTOR
New York City Suburbs

The North Shore-LIJ Health System and Cold Spring Harbor Laboratory jointly seek a Director for the Cancer Institute, headquartered at the Center for Advanced Medicine in Lake Success, New York. This individual will be an internationally renowned physician-scientist and thought-leader with an exceptional track record of building teams and leading translational research programs.

The North Shore-LIJ Health System – a fully integrated health care system, and Cold Spring Harbor Laboratory – a National Cancer Institute designated Cancer Center, recently formed a strategic affiliation focusing on basic and translational cancer research, and advancing these discoveries into the clinic.

The Director of the Cancer Institute will be responsible for the development and growth of a comprehensive program spanning basic, clinical and population research activities. The ideal candidate must have the following:

- A vision for translating fundamental diagnostic and therapeutic discovery research through clinical development within the partnership.
- A commitment to changing the paradigm of cancer care delivery to decrease the physical, as well as emotional and financial burden.
- The leadership skills to create a vision, manage and grow a cancer center within an integrated healthcare system.

The North Shore-LIJ Health System, one of the largest not-for-profit health systems in the country, treats over 19,000 unique patients with cancer annually. The North Shore-LIJ Cancer Institute is composed of over 200 members, and growing, who participate in at least one of twelve interdisciplinary disease specific Centers of Excellence that oversee clinical care, quality, research and educational initiatives.

This position will include academic appointments at both the Hofstra North Shore-LIJ School of Medicine and Cold Spring Harbor Laboratory.

Please send cover letter and curriculum vitae to: Dr. Lawrence Smith, Dean, Hofstra North Shore-LIJ School of Medicine and Physician-in-Chief at North Shore-LIJ Health System, Iscreeney@nshs.edu, (516) 823-8874. EOE M/F/D/V.
Annual Meeting
2016 • NEW ORLEANS

APRIL 16-20, 2016
ERNEST N. MORIAL
CONVENTION CENTER
NEW ORLEANS, LA

For more information visit
www.AACR.org/AACR2016

Join us in New Orleans
for the best cancer science and medicine meeting in the world...
the AACR Annual Meeting 2016!

You are invited to stretch your boundaries, form collaborations, attend sessions outside of your own area of expertise, and learn how to apply exciting new concepts, tools, and techniques to your own research.

Get your fill of ground-breaking cancer science each day, and then enjoy the great sounds, food, and culture that is New Orleans.

If you can only attend one cancer science meeting this year, the AACR’s Annual Meeting is it!

Submit your late-breaking abstract detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline. Submission date is January 26, 2016!

Be sure to register early to take advantage of reduced rates!

Become a Member!
Join the AACR and enjoy substantially reduced registration rates, the privilege of sponsoring an abstract for the Annual Meeting, funding and award opportunities, and much more.

We look forward to seeing you in New Orleans!
Goodbye thermocycler.

Enjoy more playtime with Recombinase Polymerase Amplification (RPA) the isothermal amplification that really works. RPA uses a recombinase-based process instead of thermocycling to amplify DNA, meaning real-time detection within 15 minutes.

Read over 70 RPA publications @ twistdx.co.uk/publications
Break free from qPCR
Find gene targets faster

Validating gene targets with qPCR is often slow and costly due to lengthy primer design, experimental assay optimization, and sample processing time.

QuantiGene® Plex Assays validate gene targets faster:

- No RNA purification or reverse transcription is required
- Multiplex panels of up to 80 genes are functionally validated
- One QuantiGene Plex® plate provides as much information as 20 qPCR plates

Download “The 7 best reasons to break free from qPCR”
www.ebioscience.com/breakfree-genres

Biology for a better world.

© 2015 Affymetrix, Inc. All rights reserved. For Research Use Only. Not for use in diagnostic or therapeutic procedures.